切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2017, Vol. 10 ›› Issue (06) : 686 -689. doi: 10.3877/cma.j.issn.1674-6902.2017.06.011

所属专题: 文献

论著

血浆游离DNA在非小细胞肺癌诊断中的价值
杜洁1,(), 隋永杰1, 李红艳1, 王水利1   
  1. 1. 710068 西安,陕西省人民医院健康体检中心
  • 收稿日期:2017-07-16 出版日期:2017-12-20
  • 通信作者: 杜洁
  • 基金资助:
    陕西省科技厅2013年科技惠民专项(2013K14-02-09)

Value of plasma free DNA in the diagnosis of non-small cell lung cancer

Jie Du1,(), Yongjie Sui1, Hongyan Li1, Shuili Wang1   

  1. 1. Medical examination center, Shanxi Provincial People′s Hospital, Xi′an 710068, China
  • Received:2017-07-16 Published:2017-12-20
  • Corresponding author: Jie Du
  • About author:
    Corresponding author: Du Jie, Email:
引用本文:

杜洁, 隋永杰, 李红艳, 王水利. 血浆游离DNA在非小细胞肺癌诊断中的价值[J/OL]. 中华肺部疾病杂志(电子版), 2017, 10(06): 686-689.

Jie Du, Yongjie Sui, Hongyan Li, Shuili Wang. Value of plasma free DNA in the diagnosis of non-small cell lung cancer[J/OL]. Chinese Journal of Lung Diseases(Electronic Edition), 2017, 10(06): 686-689.

目的

探讨血浆游离DNA水平在非小细胞肺癌(non-small cell lung cancer, NSCLC)中的诊断价值。

方法

选取陕西省人民医院健康中心120例健康对照者,并提取收治呼吸内科的116例非小细胞肺癌患者的,采用荧光定量PCR方法检测血浆游离DNA水平。

结果

非小细胞肺癌组患者的血浆游离DNA水平为200.70±88.54 ng/ml,健康对照组的血浆游离DNA水平为18.65±6.30 ng/ml,组间比较差异有统计学意义(P<0.01);Ⅰ/Ⅱ期非小细胞肺癌患者的血浆游离DNA水平为172.75±72.87 ng/ml,Ⅲ/Ⅳ期非小细胞肺癌血浆游离DNA水平为221.88±93.86 ng/ml,组间比较差异有统计学意义(P<0.05)。血浆游离DNA水平与患者的年龄、性别、吸烟状况及组织学类型无明显相关性(P>0.05)。

结论

血浆游离DNA是一种新发现的肿瘤标志物,可作为非小细胞肺癌早期诊断和临床分期的有效工具。

Objective

To evaluate the value of plasma free DNA in the diagnosis of non-small cell lung cancer (NSCLC).

Methods

Plasma was collected from 116 patients with non-small cell lung cancer admitted to respiratory department, and 120 healthy subjects from Medical examination center, Shanxi Provincial People′s Hospital. Plasma free DNA was extracted and detected by fluorescence quantitative polymerase chain reaction, PCR.

Results

The plasma free DNA level of healthy people was (18.65±6.30) ng/ml, and the plasma free DNA level in patients with non-small cell lung cancer was (200.70±88.54) ng/ml, the difference was statistically significant(P<0.01). The plasma free DNA content of stage Ⅰ/Ⅱ non-small cell lung cancer was (172.75±72.87) ng/ml, and the plasma circulating DNA content in stage Ⅲ/Ⅳ non-small cell lung cancer was (221.88±93.86) ng/ml, (P<0.05). There was no significant correlation between sex, age, smoking status and histological type (P>0.05).

Conclusion

Plasma circulating DNA is a potentially valuable biomarker that may be an effective tool for early diagnosis and clinical staging of non-small cell lung cancer.

图1 标准曲线图
表1 NSCLC患者血浆游离DNA水平与临床参数及组织学类型的关系(ng/ml)
1
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD].中华肺部疾病杂志(电子版), 2011, 4(1):1-6.
2
Maione P, Rossi A, Sacco PC, et al. Advance in chemotherapy in advanced non-small-cell Lung cancer[J]. Expert Opin Pharmacother, 2010, 11(18):2997-3007.
3
Diaz LA Jr, Bardelli A. Liquid Biopsies: Genotyping circulating tumor DNA[J]. J Clin Oncol, 2014, 32(6):579-586.
4
Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls[J]. J Mol Diagn, 2009, 11(3):182-185.
5
Heitzer E, Auer M, Hoffmann EM, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer[J]. Int J Cancer, 2013, 133(2):346-356.
6
Nakao M, Muramatsu H, Sone K, et al. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: a retrospective analysis[J]. Mol Clin Oncol, 2015, 3(2):403-407.
7
Shao ZM, Nguyen M. Tumor-specific DNA in plasma of breast cancer patients[J]. Anti-cancer Drngs, 2002, 13(4):353-357.
8
Lee HS, Hwang SM, Kim TS, et al. Circulating methylated septin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon[J]. Transl Oncol, 2013, 6(3):290-296.
9
Wu Y, Du X, Xue C, et al. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer[J]. Med Oncol, 2013, 30(4):737.
10
Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J]. Nat Med, 2014, 20(5):552-558.
11
Ulivi P, Mercatali L, Casoni GL, et al. Multiple marker detection in peripheral blood for NSCLC diagnosis[J]. PLoS One, 2013, 8(2):e57401.
12
Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types[J]. Mol Oncol, 2015, 9(4):783-790.
13
Szpechcinski A, Chorostowska-Wynimko J, Struniawski R, et al. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease[J]. Br J Cancer, 2015, 113(3):476-483.
14
邓水秋,欧阳学农,余宗阳,等. 晚期非小细胞肺癌血清游离DNA水平变化及意义[J]. 山东医药,2013, 53(30):6-8.
15
Madhavan D, Wallwiener M, Bents, et al. Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J]. Breast Cancer Res Treat, 2014, 146(1):163-174.
16
Perrone F, Lampis A, Bertan C, et al. Circulating free DNA in a screening program for early colorectal cancerdetection[J]. Tumori, 2014, 100(2):115-121.
17
Battaglia P, Baritono E, Remo A, et al. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer[J]. Tumori, 2014, 100(2):122-127.
18
Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015, 16(8):937-948.
19
Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma[J]. Int J Cancer, 2014, 135(9):2215-2222.
20
Tabernero J, Lenz HJ, Siena S, et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial[J]. Lancet Oncol, 2015,16(8):937-948.
[1] 何淳诺, 田志敏, 李焕玺, 吴昊越, 庄凯鹏, 周胜虎, 张浩强. 小儿发育性髋关节发育不良诊治的研究进展[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 497-504.
[2] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[3] 谢汶歆, 马乐, 刘晔, 曹晓明, 张万春. 前列腺特异性膜抗原PET/CT在肾癌诊疗中的应用价值[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 514-519.
[4] 杨慧, 郭丽娟, 冯晓丹, 李静, 黄成谋, 蔡兴锐, 覃英娇, 王远礼. 非小细胞肺癌铂类药物耐药mi RNA表达特征及预测分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 719-724.
[5] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[6] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[7] 张礼江, 沈玲佳, 施我大. 倾向性评分匹配分析奥希替尼对晚期NSCLC 预后的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 820-822.
[8] 赵蒙蒙, 黄洁, 余荣环, 王葆青. 过表达小GTP酶Rab32抑制非小细胞肺癌细胞侵袭性生长[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 512-518.
[9] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[10] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[11] 王江波, 尹一鸣, 张冠群. 外周血生物标志物在阿尔茨海默病早期诊断中的价值[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 244-249.
[12] 崔伟, 李静, 陈晓明, 张靖, 邓屹, 许荣德. 载药微球支气管动脉化疗栓塞术治疗非小细胞肺癌的研究进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 289-295.
[13] 崔伟, 邓屹, 叶苏意, 李静, 陈晓明, 张靖, 许荣德. 载药微球支气管动脉化疗栓塞术治疗罕见非小细胞肺癌的临床疗效和安全性分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 303-310.
[14] 崔伟, 叶苏意, 邓屹, 陈晓明, 张靖, 李静, 许荣德. 载药微球支气管动脉化疗栓塞术治疗难治性非小细胞肺癌的临床疗效及安全性[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 311-316.
[15] 蔡剑桥, 蒋雷. 单孔胸腔镜与开胸双袖式肺叶切除治疗非小细胞肺癌对比[J/OL]. 中华胸部外科电子杂志, 2024, 11(04): 225-230.
阅读次数
全文


摘要